Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use
- PMID: 9530544
- DOI: 10.2165/00003495-199855030-00005
Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use
Abstract
In the absence of evidence that eradication of HIV from an infected individual is feasible, the established goal of antiretroviral therapy is to reduce viral load to as low as possible for as long as possible. Achieving this with the currently available antiretroviral agents involves appropriate selection of components of combination regimens to obtain an optimal antiviral response. In addition, consideration of a plan for a salvage or second-line regimen is required if initial therapy fails to achieve an optimal response or should loss of virological control occur despite effective initial therapy. Such a planned approach, based on consideration of the likely modes of therapeutic failure (viral resistance, cellular resistance, toxicity) could be called rational sequencing. Choice of therapy should never involve compromise in terms of activity. However, the choice of drug should also be guided by tolerability profiles and considerations of coverage of the widest range of infected cells, compartmental penetration, pharmacokinetic interactions and, importantly, the ability of an agent or combination to limit future therapeutic options through selection of cross-resistant virus. Available clinical end-point data clearly indicate that combination therapy is superior to monotherapy, with clinical and surrogate marker data supporting the use of triple drug (or double protease inhibitor) combinations over double nucleoside analogue combinations. Thus, 3-drug therapy should represent current standard practice in a nontrials setting. Treatment should be considered as early as practical, and may be best guided by measurement of viral load, with a range of other markers having potential utility in individualising treatment decisions. Therapeutic failure may be defined clinically, immunologically or, ideally, virologically, and should prompt substitution of at least 2, and preferably all, components of the treatment regimen. Drug intolerance may also be best managed by rational substitution.
Similar articles
-
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.Prescrire Int. 2004 Aug;13(72):144-50. Prescrire Int. 2004. PMID: 15532140
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Delavirdine: a review of its use in HIV infection.Drugs. 2000 Dec;60(6):1411-44. doi: 10.2165/00003495-200060060-00013. Drugs. 2000. PMID: 11152019 Review.
-
[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Enferm Infecc Microbiol Clin. 2009. PMID: 19246124 Spanish.
-
Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.AIDS. 1999 Sep;13 Suppl 1:S49-59. AIDS. 1999. PMID: 10546785 Review.
Cited by
-
Potential drug-drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals.Int J Infect Dis. 2019 Jun;83:98-101. doi: 10.1016/j.ijid.2019.04.009. Epub 2019 Apr 13. Int J Infect Dis. 2019. PMID: 30991140 Free PMC article.
-
Nelfinavir. A review of its therapeutic efficacy in HIV infection.Drugs. 1998 Jul;56(1):147-67. doi: 10.2165/00003495-199856010-00013. Drugs. 1998. PMID: 9664204 Review.
-
Didanosine: an updated review of its use in HIV infection.Drugs. 1999 Dec;58(6):1099-135. doi: 10.2165/00003495-199958060-00009. Drugs. 1999. PMID: 10651392 Review.
-
Abacavir: a review of its clinical potential in patients with HIV infection.Drugs. 2000 Aug;60(2):447-79. doi: 10.2165/00003495-200060020-00015. Drugs. 2000. PMID: 10983741 Review.
-
When to Start Antiretroviral Therapy and What to Start With-- A European Perspective.Curr Infect Dis Rep. 2003 Aug;5(4):349-357. doi: 10.1007/s11908-003-0013-y. Curr Infect Dis Rep. 2003. PMID: 12866987
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical